ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027

LYON, France, April 21, 2026–Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the establishment of a shareholder loan agreement with Vester Finance, repayable in new shares, with an option for the Company to repay in cash under certain conditions.